In the next 3-5 years, China's innovative pharmaceutical companies will usher in a big test! How to deal with it?

【Pharmaceutical Network Market Analysis】Benefiting from the multiple resonances of favorable policies, capital increases, talent return, etc.
, China's enthusiasm for pharmaceutical innovation is high, and a large number of Biotech enterprises have entered the stage
of batch commercialization after continuous research and development investment.

However, there are opportunities and challenges, the industry expects that in the next 3-5 years, China's innovative pharmaceutical companies will usher in a big test, including capital markets, product performance, domestic and overseas market competition, etc.
How to deal with it is an urgent problem for enterprises
to think about.

As of now, the semi-annual report of listed pharmaceutical companies has basically been disclosed, and from the data point of view, there are both joys and worries
.

For example, the innovative drug company Fuhong Henlius achieved operating income of 1.
2894 billion yuan in the first half of the year, an increase of about 103.
5% over the same period last year, mainly from the sales revenue and licensing income brought by the successive commercialization of a variety of products
.

Among them, the domestic sales of the core product Hanquyou ® increased by about 178.
2%
over the same period last year.

Affected by the price reduction and epidemic situation, Fosun Pharma's performance in the first half of the year was under pressure, and its net profit fell by 37.
67%
year-on-year.

In this regard, Fosun Pharma is also actively responding to challenges, including the division-level splitting of major businesses since the beginning of the year, strengthening innovative product research and development, further layout of the international market, lean operations, etc.
, to cope with the new round of innovation and upgrading
that the pharmaceutical industry will face.

The industry believes that the collection of drugs has become normalized, and this policy brings pressure on pharmaceutical companies to control costs through price for quantity, and also squeezes out inflated water, allowing the industry to move towards the direction
of standardized health.

In the long run, pharmaceutical companies need to standardize their operations, strengthen innovation, and seek new business growth points
.

At the same time, with the rapid development of the domestic innovative drug industry, many new drug research and development tracks have become too crowded, and pharmaceutical companies need to seek differentiation
.

The data shows that in 2021, the approval of new drugs in China will accelerate, and a total of 82 new molecules will be listed in China for the first time, of which the proportion of new drugs developed by local enterprises will reach 35.
8%, which is the same
as imported new drugs.

Since the second half of 2021, the New Deal has been introduced to crack down on "pseudo-innovation", and the biomedical investment and financing market has cooled down significantly, in this context, many pharmaceutical companies have shifted from the fiercely competitive domestic market to the international market, with the help of License out, independent "going to sea" and other ways to go to sea
.

"Innovative drugs going overseas is the trend of the times, and overseas markets will become a must for innovative pharmaceutical companies in the future
.
"
The industry said that with the increasing cost of innovative research and development and the low return on investment in the single market, the layout of pharmaceutical companies in the international market is a new way out, which is also conducive to enhancing the competitiveness
of innovative enterprises.

However, it is not easy for domestic new drugs to go to sea
.

Although domestic drugs such as Zebutinib of BeiGene and legendary biocar-T cell therapy product Sidakiola have been successfully listed in the United States to encourage the industry, there have also been cases in which
a number of local pharmaceutical products such as Cinda Bio, Hehuang Pharmaceutical, and Junshi Bio have been frustrated in the United States.

The analysis believes that from the experience of local pharmaceutical companies in the United States listing application setbacks, it is mainly because local pharmaceutical companies do not have enough understanding of the laws and regulations of overseas drug regulatory departments such as the FDA, and they are not familiar with the market environment of the target country and have insufficient grasp of product competition
.

This also reminds local pharmaceutical companies that have laid out overseas, do not rush to make quick profits, should always pay attention to changes in FDA standards, actively communicate and interact with local regulatory agencies, and at the same time need to strengthen basic scientific research and investment, adhere to the clinical value-oriented, strengthen the research and development of "first-in-class" innovative drugs, and also avoid crowded tracks through international cooperation, focus on research and development of
unmet important varieties.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.